Translating Regenerative Medicine to the Clinic

Dr Laurence is pursuing the pathophysiology of cardiovascular and skeletal abnormalities linked to HIV disease and its therapies at Weill Cornell. Dr Laurence is the editor-in-chief of Translational Medicine, which Elsevier co-publishes with the CSCTR. Dr. Pedro Baptista is originally from Portugal, where he graduated from the School of Pharmacy of the University of Lisbon. He completed his doctoral dissertation at the Gulbenkian Ph.D. Program in Biomedicine. He is currently a Group Leader at the Health Research Institute of Aragon in Zaragoza, Spain and the founder of the Organ Bioengineering and Regenerative Medicine Laboratory at this institution. He is also an Assistant Professor at the Department of Biomedical and Aerospace Engineering at University Carlos III of Madrid, Spain. He is one of the founders and the Deputy Chairman of the European Association for the Study of the Liver Consortium for Regenerative Hepatology and currently the Deputy Secretary General and an elected Board Governor of the European Society for Artificial Organs. His current research focuses on creating bioengineered livers that can finally make the long-term transplantation of these lab-grown organs a reality.Dr. Pedro Baptista is originally from Portugal, where he graduated from the School of Pharmacy of the University of Lisbon. He completed his doctoral dissertation at the Gulbenkian Ph.D. Program in Biomedicine. He is currently a Group Leader at the Health Research Institute of Aragon in Zaragoza, Spain and the founder of the Organ Bioengineering and Regenerative Medicine Laboratory at this institution. He is also an Assistant Professor at the Department of Biomedical and Aerospace Engineering at University Carlos III of Madrid, Spain. He is one of the founders and the Deputy Chairman of the European Association for the Study of the Liver Consortium for Regenerative Hepatology and currently the Deputy Secretary General and an elected Board Governor of the European Society for Artificial Organs. His current research focuses on creating bioengineered livers that can finally make the long-term transplantation of these lab-grown organs a reality. Anthony Atala, MD, is the G. Link Professor and Director of the Wake Forest Institute for Regenerative Medicine, and the W. Boyce Professor and Chair of Urology. Dr. Atala is a practicing surgeon and a researcher in the area of regenerative medicine. Fifteen applications of technologies developed in Dr. Atala's laboratory have been used clinically. He is Editor of 25 books and 3 journals. Dr. Atala has published over 800 journal articles and has received over 250 national and international patents. Dr. Atala was elected to the Institute of Medicine of the National Academies of Sciences, to the National Academy of Inventors as a Charter Fellow, and to the American Institute for Medical and Biological Engineering. Dr. Atala has led or served several national professional and government committees, including the National Institutes of Health working group on Cells and Developmental Biology, the National Institutes of Health Bioengineering Consortium, and the National Cancer Institute’s Advisory Board. He is a founding member of the Tissue Engineering Society, Regenerative Medicine Foundation, Regenerative Medicine Manufacturing Innovation Consortium, Regenerative Medicine Development Organization, and Regenerative Medicine Manufacturing Society.

Introduction: Regenerative Medicine for Cardiovascular Disease-A Good Start
PART I: STEM CELLS: 
Chapter 1: Introduction and Overview of Stem Cells
Chapter 2: Mechanistic Insights from Pathologic Perspective
Chapter 3: Large Animal Models to Study Stem Cell Therapy
Section I. Body’s Native Repair Mechanisms
Chapter 4. Evolution of understanding of the mechanisms of repair    
Chapter 5: Impact of Age on Stem Cell Function
Section II: Autologous Bone Marrow
Chapter 6: Bone Marrow Mononuclear Cells
Chapter 7: Chronic Limb Ischemia
Chapter 8: Chronic/Refractory Angina
Chapter 9: Acute Myocardial Infarction
A. European Experience:  Andreas Zeiher
B. US Experience: Jay Traverse
Chapter 10: Chronic Ischemic Heart Failure
Section III:  Autologous Adipose Derived Regenerative Cells
Chapter 11: Adipose Tissue
Section IV: Allogeneic Alternatives to Autologous Bone Marrow
Chapter 12: Overview of MSCs    
Chapter 13: Allogeneic vs Autologous Source: Comparative Effects
Chapter 14: Use of MSCs for AMI
Chapter 15: Combined Cell Strategies
Chapter 16: Heart Failure
Section V: Cardiac Progenitor Cells
Chapter 17:  C-Kit+ cells
Chapter 18:  Cardiospheres
Section VI: Other Allogeneic Sources of Stem Cells
Chapter 19:  Umbilical Cord, Placenta, Endometrium
Section VII. Genetic Engineering/Cell Transformation
Chapter 20:  Genetic Engineering of Fibroblasts to Cardiomyocytes
Chapter 21:  Transformation to inducible Pleuripotent Stem Cells
Chapter 22:  Transformation to MAPC's
Section VIII: METHODS OF DELIVERY: 
Chapter 23.  Transcoronary and Endocardial
Chapter 24.  Retrograde and Epicardial
Part II. TISSUE ENGINEERING:
Chapter 25.  Epicardial Patch
Chapter 26.  Matrix Scaffolds
Chapter 27.  Matrix plus cells
Chapter 28.  Biomaterial
Chapter 29:  Organogenesis
Part III. GENE THERAPY:
Chapter 30:  Pre-clinical Identification of target genes
Chapter 31:  SERCA-2a gene for recovery of inotropic function
Chapter 32:  SDF-1 Gene for Heart Failure Non-Inotropic Mechanisms
Chapter 33:  Gene Therapy for Angiogenesis: Chronic Limb Ischemia
Chapter 34:  Stem Cells Target Gene Transfected Stem Cells
Part IV: FUTURE DIRECTIONS:
Chapter 35:  CCTRN: Past, Present, and Vision for the Future
Chapter 36:  Signature of Responders-lessons from Bio-Repository
Chapter 37:  Adjunctive therapy with LVADs for Recovery
Chapter 38:  Trials in Non-Ischemic Heart Failure 
Chapter 39:  Enhancing Stem Cell Homing for Tissue Repair
Chapter 40:  Stroke: Pre-Clinical and Clinical Trial Data
SUMMARY